Dr. Shah on Unmet Needs With CAR T-Cell Therapies in Hematologic Malignancies

Video

Nirav N. Shah, MD, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

Nirav N. Shah, MD, associate professor, the Medical College of Wisconsin, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

Advancements in CAR T-cell therapy have led to effective and paradigm-shifting strategies for treating patients with B-cell malignancies, Shah says. However, improvements are needed of treatment development and delivery, as well as improved toxicity management for patients with these agents, Shah emphasizes.

CAR T-cell therapy can be associated with lead to several adverse effects (AEs), Shah continues. Long-term effects include low B-cell counts or the inability to produce antibodies following treatment, Shah explains. Additionally, short-term AEs include cytokine release syndrome and ICANS, Shah adds.

Furthermore, CAR T-cell therapy invokes logistical challenges, such as the cost of manufacturing and long wait-times for patients, Shah concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD